GSK-2302024A

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameGSK-2302024A

Drug Alias NameWT1-A10+AS15 ASCIGSK-2302024A

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited StatesRussian Federation +[7]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsBreast Neoplasms

ATC CodeN/A